Payment overview · 2025
General Payments
$1,606.43
82 reported records · 13 companies
Healthcare provider profile · identity verified
Adam D. Zeitlin, DO
Allopathic & Osteopathic Physicians|Family Medicine · FLUSHING, NY · NPI 1386745578
Verified facts
What the public records show
CMS Open Payments records show Adam D. Zeitlin, DO received $1,606.43 in general payments during 2025 across 82 reported records.
Neurocrine BioSciences, Inc. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ingrezza, Jardiance, Kerendia, Mounjaro, Otezla, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $243.21 | 15.1% | 17 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $234.96 | 14.6% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.54 | 12.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.51 | 9.4% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $148.09 | 9.2% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $137.21 | 8.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.47 | 6.1% | 4 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $90.09 | 5.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.89 | 5.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.19 | 5.4% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $77.06 | 4.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.00 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.21 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,606.43 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $243.21 | 17 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $234.96 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.51 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $148.09 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $137.21 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.26 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.28 | 6 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $90.09 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $77.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.17 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.17 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.52 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $61.24 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 152 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 223 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
188 | 38 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2004 | 319 |
| Amlodipine Besylate | Amlodipine Besylate | 1566 | 269 |
| Levothyroxine Sodium | Levothyroxine Sodium | 996 | 161 |
| Tamsulosin Hcl | Tamsulosin Hcl | 914 | 136 |
| Furosemide | Furosemide | 820 | 178 |
| Eliquis | Apixaban | 784 | 114 |
| Losartan Potassium | Losartan Potassium | 738 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 708 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 664 | 120 |
| Metformin Hcl | Metformin Hcl | 656 | 117 |
| Simvastatin | Simvastatin | 509 | 81 |
| Gabapentin | Gabapentin | 489 | 111 |
| Mirtazapine | Mirtazapine | 442 | 67 |
| Lisinopril | Lisinopril | 439 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 422 | 67 |
| Omeprazole | Omeprazole | 402 | 83 |
| Carvedilol | Carvedilol | 401 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 394 | 57 |
| Finasteride | Finasteride | 388 | 57 |
| Januvia | Sitagliptin Phosphate | 384 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 372 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 359 | 73 |
| Famotidine | Famotidine | 347 | 57 |
| Donepezil Hcl | Donepezil Hcl | 329 | 45 |
| Trazodone Hcl | Trazodone Hcl | 307 | 63 |
| Montelukast Sodium | Montelukast Sodium | 304 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 300 | 59 |
| Azithromycin | Azithromycin | 242 | 184 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 230 | 64 |
| Sertraline Hcl | Sertraline Hcl | 229 | 38 |
| Jardiance | Empagliflozin | 223 | 43 |
| Meloxicam | Meloxicam | 209 | 84 |
| Levetiracetam | Levetiracetam | 199 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 189 | 48 |
| Trulicity | Dulaglutide | 188 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 187 | 37 |
| Spironolactone | Spironolactone | 187 | 38 |
| Risperidone | Risperidone | 186 | 26 |
| Memantine Hcl | Memantine Hcl | 181 | 19 |
| Atenolol | Atenolol | 172 | 28 |
| Clonazepam | Clonazepam | 170 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 164 | 29 |
| Ozempic | Semaglutide | 162 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 161 | 116 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 34 |
| Allopurinol | Allopurinol | 157 | 33 |
| Alprazolam | Alprazolam | 156 | 37 |
| Nifedipine Er | Nifedipine | 155 | 27 |
| Farxiga | Dapagliflozin Propanediol | 152 | 29 |
| Enalapril Maleate | Enalapril Maleate | 148 | 28 |
| Myrbetriq | Mirabegron | 144 | 28 |
| Vascepa | Icosapent Ethyl | 139 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 126 | 32 |
| Entresto | Sacubitril/Valsartan | 124 | 20 |
| Mupirocin | Mupirocin | 124 | 62 |
| Metformin Hcl Er | Metformin Hcl | 123 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 122 | 36 |
| Alendronate Sodium | Alendronate Sodium | 120 | 24 |
| Xarelto | Rivaroxaban | 117 | 19 |
| Ramipril | Ramipril | 116 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 115 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 28 |
| Buspirone Hcl | Buspirone Hcl | 112 | 17 |
| Linzess | Linaclotide | 112 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 47 |
| Baclofen | Baclofen | 108 | 18 |
| Latanoprost | Latanoprost | 106 | 22 |
| Hydrocortisone | Hydrocortisone | 105 | 52 |
| Bupropion Xl | Bupropion Hcl | 104 | 16 |
| Divalproex Sodium | Divalproex Sodium | 104 | 15 |
| Glipizide | Glipizide | 104 | 17 |
| Meclizine Hcl | Meclizine Hcl | 100 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 96 | 13 |
| Olanzapine | Olanzapine | 96 | 12 |
| Aripiprazole | Aripiprazole | 91 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 90 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 15 |
| Pregabalin | Pregabalin | 90 | 14 |
| Potassium Chloride | Potassium Chloride | 88 | 20 |
| Warfarin Sodium | Warfarin Sodium | 88 | suppressed |
| Synthroid | Levothyroxine Sodium | 86 | 17 |
| Tradjenta | Linagliptin | 81 | suppressed |
| Ezetimibe | Ezetimibe | 79 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 75 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 75 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 29 |
| Labetalol Hcl | Labetalol Hcl | 73 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 14 |
| Lidocaine | Lidocaine | 72 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 16 |
| Nystatin | Nystatin | 67 | 33 |
| Ammonium Lactate | Ammonium Lactate | 64 | 21 |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 62 | 21 |
| Valsartan | Valsartan | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 58 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 11 |
| Glipizide Er | Glipizide | 56 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Lamotrigine | Lamotrigine | 54 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 54 | 11 |
| Digoxin | Digoxin | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 29 |
| Repaglinide | Repaglinide | 52 | suppressed |
| Glimepiride | Glimepiride | 51 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Amantadine | Amantadine Hcl | 47 | suppressed |
| Folic Acid | Folic Acid | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 44 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | suppressed |
| Irbesartan | Irbesartan | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Gemtesa | Vibegron | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Enulose | Lactulose | 41 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 41 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 16 |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 11 |
| Hydroxyurea | Hydroxyurea | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Anastrozole | Anastrozole | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 20 |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Prednisone | Prednisone | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Tobramycin | Tobramycin | 36 | 24 |
| Haloperidol Lactate | Haloperidol Lactate | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 32 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Glumetza | Metformin Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Bicalutamide | Bicalutamide | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 26 | suppressed |
| Nyamyc | Nystatin | 26 | 12 |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 11 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Mirabegron Er | Mirabegron | 25 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 25 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Phenytoin | Phenytoin | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 23 | 16 |
| Fluphenazine Hcl | Fluphenazine Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Clindamycin Phosphate | Clindamycin Phosphate | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Letrozole | Letrozole | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 21 | 16 |
| Belsomra | Suvorexant | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 15 |
| Metronidazole | Metronidazole | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 13 |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Jublia | Efinaconazole | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Crestor | Rosuvastatin Calcium | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Brinzolamide | Brinzolamide | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Lipitor | Atorvastatin Calcium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 11 | suppressed |
| Travatan Z | Travoprost | 11 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,606.43 · 82 records | Neurocrine BioSciences, Inc. | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, Dexcom G6 Transmitter, FARXIGA, GEMTESA, INGREZZA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, XIFAXAN, ZORYVE, ZTLido | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error